Stablecoin Development Corporation (SDEV) Stock Price

SDEVStock

$1.04−75.38%52W

Market Cap$52.64M

P/E—

PEG Ratio—

Div yield0.00%

Beta0.05

SDEV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-59.15%

Price vs S&P 500 (4W)-5.66%

VGM Score43.24

Indicated Dividend Yield (Annual)0.00%

P/CF (Annual)18.73x

Book Value / Share (Quarterly)$5.20

Revenue Growth (3Y)5.12%

Cash Flow / Share (Quarterly)$0.08

Price vs S&P 500 (YTD)-107.99%

Gross Margin (TTM)54.56%

Net Profit Margin (TTM)2147.91%

EPS (TTM)$-0.76

10-Day Avg Trading Volume1.93M

EPS Excl Extra (TTM)$-0.76

Revenue Growth (5Y)8.19%

EPS (Annual)$-2.13

Dividend / Share (Annual)$0.37

ROI (Annual)-216.58%

Gross Margin (Annual)66.26%

Net Profit Margin (5Y Avg)-78.66%

Cash / Share (Quarterly)$0.69

P/E Basic Excl Extra (TTM)0.10x

Revenue Growth QoQ (YoY)-78.66%

ROA (Last FY)-211.01%

Revenue Growth TTM (YoY)-74.73%

EBITD / Share (TTM)$0.36

ROE (5Y Avg)-306.84%

Operating Margin (TTM)81.97%

Cash Flow / Share (Annual)$0.11

P/B Ratio0.36x

P/B Ratio (Quarterly)0.29x

Net Income / Employee (Annual)$-3,611,500

Net Interest Coverage (TTM)-399.56x

ROA (TTM)1049.51%

EPS Incl Extra (Annual)$-2.13

Current Ratio (Annual)7.60x

Quick Ratio (Quarterly)5.23x

3-Month Avg Trading Volume0.78M

52-Week Price Return-75.38%

EV / Free Cash Flow (Annual)11.92x

P/E Incl Extra (TTM)0.10x

Revenue / Employee (TTM)$12,829,000

P/S Ratio (Annual)5.17x

Asset Turnover (Annual)2.86x

52-Week High$99.75

Operating Margin (5Y Avg)-76.31%

EPS Excl Extra (Annual)$-2.13

26-Week Price Return-47.91%

Quick Ratio (Annual)7.33x

13-Week Price Return-24.32%

Total Debt / Equity (Annual)0.34x

Current Ratio (Quarterly)5.33x

Enterprise Value$32.21M

Revenue / Share Growth (5Y)-23.01%

Asset Turnover (TTM)0.28x

Revenue / Employee (Annual)$4,890,500

Inventory Turnover (Annual)1.81x

Pretax Margin (Annual)-73.71%

Cash / Share (Annual)$0.32

3-Month Return Std Dev109.11%

Gross Margin (5Y Avg)60.92%

Net Income / Employee (TTM)$261,296,000

ROE (Last FY)-290.89%

Net Interest Coverage (Annual)2854.67x

EPS Basic Excl Extra (Annual)$-2.13

P/FCF (TTM)5.44x

Receivables Turnover (TTM)5.28x

EV / Free Cash Flow (TTM)14.49x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.76

Receivables Turnover (Annual)17.04x

ROI (TTM)1136.53%

P/S Ratio (TTM)1.97x

Pretax Margin (5Y Avg)-78.61%

Revenue / Share (Annual)$2.88

Price vs S&P 500 (52W)-93.70%

P/E Ratio (TTM)0.10x

Year-to-Date Return-96.03%

5-Day Price Return20.48%

EPS Normalized (Annual)$-2.13

ROA (5Y Avg)-95.83%

Net Profit Margin (Annual)-73.85%

Month-to-Date Return-2.61%

EBITD / Share (Annual)$-1.71

Operating Margin (Annual)-59.83%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)22.77x

ROI (5Y Avg)-146.64%

P/E Excl Extra (TTM)0.10x

LT Debt / Equity (Quarterly)1.65x

EPS Basic Excl Extra (TTM)$-0.76

Inventory Turnover (TTM)1.81x

Pretax Margin (TTM)2161.21%

Price vs S&P 500 (13W)-27.12%

Beta0.05x

P/FCF (Annual)18.73x

Revenue / Share (TTM)$0.15

ROE (TTM)1138.58%

52-Week Low$0.93

vGradeB

gGradeD

mGradeD

vgmGradeC

SDEV Earnings Surprise History

Q1 24-26.72est. -26.25

Q2 24-4.86est. -6.13

Q3 24-2.97est. -1.52

Q4 24-1.99est. -1.20

SDEV Analyst Recommendations

Jun 2025

Jul 2025

Aug 2025

Oct 2025

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
SDEVStablecoin Development Corporation	B	D	D	$1.04
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Stablecoin Development Corporation

Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.